Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.
Thank you. Please check your inbox to confirm.
Maureen Ferran, The Conversation
Maureen Ferran, The Conversation
Leave your feedback
On Sept 22, 2021, Johnson & Johnson released data that answers two questions many people have likely been wondering about its vaccine: How good is it against the delta variant, and do I need a booster? Maureen Ferran is a virologist at the Rochester Institute of Technology and has been keeping tabs on the Johnson & Johnson vaccine. She broke down the new data and explains what it all means.
Early clinical trial data released in January 2021 showed that four weeks after the first dose, the Johnson & Johnson single–shot vaccine was 66.3% effective at preventing COVID-19 infection. The initial studies also showed that it was 85% effective at preventing severe or critical disease.
But the original clinical trials and most subsequent studies were done before the delta variant became responsible for almost all of the COVID-19 cases in the U.S. Early studies suggest that although COVID-19 vaccines are still effective against this variant, in general their efficacy is lower compared to protection against the original strain.
On Sept. 21, 2021, Johnson and Johnson announced the results of a large, real-world Phase 3 clinical trail of their COVID-19 vaccine. This study collected data from March 1, 2020 through July 31, 2021 and found that the effectiveness of the vaccine did not diminish over the duration of the study, even after the Delta variant became dominant in the U.S. The one-dose vaccine was 79% protective against COVID-19 infections and 81% protective for COVID-19-related hospitalizations. This indicates that a single Johnson & Johnson shot performs well, even in the presence of Delta and other variants.
The amount of neutralizing antibodies in a person – antibodies that defend a cell from the coronavirus – is an accurate measure of protection within the first several months after vaccination. Studies show that individuals who received a Johnson & Johnson or an mRNA vaccine continue to produce some level of antibodies for at least six months after vaccination. However, neutralizing antibody levels generally start to wane over time and some evidence suggests that immunity provided by the Pfizer mRNA vaccine does the same.
This may sound bad, but it isn’t clear that lower antibody levels correlates with an increased risk of severe infection. The immune system’s long-term surveillance is done by “memory” immune cells that will prevent or reduce disease severity if a person is exposed to the virus at a later time.
Therefore scientists have been collecting real-world data from vaccinated people to determine when they may become vulnerable to infection again with and without a booster shot.
In addition to the results of the single–shot study, on Sept 21, 2021, Johnson & Johnson also released data about booster shots. The trial gave people a second dose of the Johnson & Johnson vaccine either two or six months after the first dose. In both cases, it increased people’s defense against COVID–19.
When given two months after the first dose, protection against moderate to severe disease increased from 85% to 94% and the amount of neutralizing antibodies increased four-fold. If the booster was administered six months after the first shot, antibody levels increased 12-fold when measured four weeks after the booster was given.
These findings suggest that although a single dose of the Johnson & Johnson vaccine provides strong, durable protection, people may still benefit from a booster because it improves the vaccine’s efficacy.
One important question is whether someone who received the Johnson & Johnson shot should get a second Johnson & Johnson dose or mix and match – get a second dose of a different vaccine. As of late September, the FDA seems more likely to approve a second dose of the Johnson & Johnson vaccine because there isn’t much data yet about a mix and match strategy.
The vast majority of vaccines – including the Johnson & Johnson and mRNA vaccines – produce common side effects such as pain at the injection site, headache, fatigue, muscle and joint pain, chills and fever.
The recent study did not monitor side effects from the booster in detail, but according to Johnson & Johnson, the safety of the vaccine remained consistent and was generally well-tolerated when administered as a booster. Overall, researchers have repeatedly found that despite some rare complications, the benefits of the Johnson & Johnson vaccine far outweigh the risks.
A recent CDC study showed that unvaccinated people are almost five times more likely to be infected by the coronavirus and 29 times more likely to be hospitalized with COVID-19 compared to fully vaccinated individuals. Therefore, all the evidence suggests that the millions of Americans who are able to get vaccinated but are choosing not to are putting themselves – and others – at serious risk.
On Sept, 22, 2021, the FDA approved booster shots for people who received the Pfizer vaccine and are over 65 years of age, at risk of severe COVID illness or whose occupations put them at greater risk of exposure. Booster shots of the Johnson & Johnson or Moderna vaccines are not yet approved, but on September 19th Dr. Anthony Fauci said that the FDA could review booster data for the Moderna and Johnson & Johnson vaccines within a few weeks.
Editor’s note: Johnson & Johnson is a funder for the PBS NewsHour.
Portions of this article originally appeared in a previous article originally published on Aug. 27, 2021. This article is republished from The Conversation under a Creative Commons license. Read the original article.
Maureen Ferran is an associate professor of biology at Rochester Institute of Technology.
Support Provided By:
Additional Support Provided By: